Featured Research

from universities, journals, and other organizations

Genetic regulation of metabolomic biomarkers: Paths to cardiovascular diseases and type 2 diabetes

Date:
January 30, 2012
Source:
University of Helsinki
Summary:
Scientists have revealed eleven new genetic regions associated with the blood levels of the metabolites, including new loci affecting well-established risk markers for cardiovascular disease and potential biomarkers for type 2 diabetes. The findings may help in elucidating the processes leading to common diseases.

The research group at the Institute for Molecular Medicine Finland (FIMM) has revealed eleven new genetic regions associated with the blood levels of the metabolites, including new loci affecting well-established risk markers for cardiovascular disease and potential biomarkers for type 2 diabetes.

In a study to the genetic variance of human metabolism, researchers have identified thirty one regions of the genome that were associated with levels of circulating metabolites, i.e., small molecules that take part in various chemical reactions of human body. Many of the studied metabolites are biomarkers for cardiovascular disease or related disorders, thus the loci uncovered may provide valuable insight into the biological processes leading to common diseases.

Laboratory tests used in the clinic typically monitor one or few circulating metabolites. The researchers at the Institute for Molecular Medicine Finland (FIMM) used a high throughput method called nuclear magnetic resonance (NMR) that can measure more than hundred different metabolites in one assay. This provides a much more in-depth picture of circulating metabolic compounds.

"Using this extensive analysis in thousands of people, we could identify a large number of genetic loci regulating the level of compounds circulating in the blood stream," says Dr. Samuli Ripatti, the leader of the study.

The team assayed 117 detailed metabolic markers, including lipoprotein subclasses, amino acids and lipids, and conducted the largest genome-wide association analysis of this type, in terms of study sample size of 8330 individuals from six Finnish population-based cohorts and 7.7 million genomic markers studied. They revealed, in total, 31 genetic regions associated with the blood levels of the metabolites.

Eleven of the loci had not been previously shown to be associated with any metabolic measures.

Among the findings were two new loci affecting serum cholesterol subclass measures, well-established risk markers for cardiovascular disease, and five new loci affecting levels of amino acids recently discovered to be potential biomarkers for type 2 diabetes. The discovered variants have significant effects on the metabolite levels, the effect sizes being in general considerably larger than the known common variants for complex disease have.

Also, using Finnish twin pair samples, the researchers indicated that the metabolite levels show a high degree of heritability. "This result suggests that the studied metabolites are describing better the underlying biology than the routinely used laboratory tests. Therefore, the study provides further support for the use of detailed data on multitude of metabolites in genetic studies to provide novel biological insights and to help in elucidating the processes leading to common diseases," Dr. Ripatti says.


Story Source:

The above story is based on materials provided by University of Helsinki. Note: Materials may be edited for content and length.


Journal Reference:

  1. Johannes Kettunen, Taru Tukiainen, Antti-Pekka Sarin, Alfredo Ortega-Alonso, Emmi Tikkanen, Leo-Pekka Lyytikäinen, Antti J Kangas, Pasi Soininen, Peter Würtz, Kaisa Silander, Danielle M Dick, Richard J Rose, Markku J Savolainen, Jorma Viikari, Mika Kähönen, Terho Lehtimäki, Kirsi H Pietiläinen, Michael Inouye, Mark I McCarthy, Antti Jula, Johan Eriksson, Olli T Raitakari, Veikko Salomaa, Jaakko Kaprio, Marjo-Riitta Järvelin, Leena Peltonen, Markus Perola, Nelson B Freimer, Mika Ala-Korpela, Aarno Palotie, Samuli Ripatti. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nature Genetics, 2012; DOI: 10.1038/ng.1073

Cite This Page:

University of Helsinki. "Genetic regulation of metabolomic biomarkers: Paths to cardiovascular diseases and type 2 diabetes." ScienceDaily. ScienceDaily, 30 January 2012. <www.sciencedaily.com/releases/2012/01/120129151007.htm>.
University of Helsinki. (2012, January 30). Genetic regulation of metabolomic biomarkers: Paths to cardiovascular diseases and type 2 diabetes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/01/120129151007.htm
University of Helsinki. "Genetic regulation of metabolomic biomarkers: Paths to cardiovascular diseases and type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2012/01/120129151007.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins